脊柱关节炎：白细胞介素-17A阻断可改善强直性脊柱炎。 - Suppr

Suppr

超能文献

Spondyloarthropathies: IL-17A blockade ameliorates ankylosing spondylitis.

作者信息

Duarte João H

出版信息

Nat Rev Rheumatol. 2016 Feb;12(2):72. doi: 10.1038/nrrheum.2016.7. Epub 2016 Jan 22.

DOI:10.1038/nrrheum.2016.7

PMID:26794859

Abstract

摘要

相似文献

Spondyloarthropathies: IL-17A blockade ameliorates ankylosing spondylitis.

Nat Rev Rheumatol. 2016 Feb;12(2):72. doi: 10.1038/nrrheum.2016.7. Epub 2016 Jan 22.

The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.

Expert Rev Clin Immunol. 2019 Feb;15(2):123-134. doi: 10.1080/1744666X.2019.1561281. Epub 2019 Jan 8.

IL-17 Blockade in Psoriasis.

Cell. 2016 Dec 15;167(7):1669. doi: 10.1016/j.cell.2016.11.044.

Efficacy and Safety of Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Meta-Analysis.

Monoclon Antib Immunodiagn Immunother. 2020 Oct;39(5):160-166. doi: 10.1089/mab.2020.0022. Epub 2020 Oct 1.

IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis.

Arthritis Res Ther. 2018 Jun 7;20(1):115. doi: 10.1186/s13075-018-1582-3.

Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis.

Expert Opin Biol Ther. 2019 Jan;19(1):55-64. doi: 10.1080/14712598.2019.1554053. Epub 2018 Dec 7.

The role of secukinumab in the treatment of ankylosing spondylitis.

Immunotherapy. 2015;7(12):1241-7. doi: 10.2217/imt.15.93. Epub 2015 Nov 23.

Secukinumab (AIN457) in the treatment of ankylosing spondylitis.

Expert Opin Biol Ther. 2016;16(5):711-22. doi: 10.1517/14712598.2016.1167183.

New targeted therapies in spondyloarthritis: what are the limits?

Immunotherapy. 2019 May;11(7):557-560. doi: 10.2217/imt-2019-0007.

IL-17 for therapy.

J Dermatol Sci. 2017 Sep;87(3):221-227. doi: 10.1016/j.jdermsci.2017.06.010. Epub 2017 Jun 15.

引用本文的文献

Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison.

Arthritis Res Ther. 2019 Jun 7;21(1):142. doi: 10.1186/s13075-019-1911-1.

Unmet needs in the treatment of ankylosing spondylitis: a long-term observational study from a single university center.

Rheumatol Int. 2019 Apr;39(4):663-668. doi: 10.1007/s00296-019-04277-w. Epub 2019 Mar 15.

Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.

RMD Open. 2017 Dec 28;3(2):e000592. doi: 10.1136/rmdopen-2017-000592. eCollection 2017.

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Nat Rev Drug Discov. 2017 Dec 28;17(1):78. doi: 10.1038/nrd.2017.267.

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.

Arthritis Res Ther. 2017 Dec 22;19(1):285. doi: 10.1186/s13075-017-1490-y.

Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):1020-1029. doi: 10.1002/acr.23233. Epub 2017 Jun 7.

Secukinumab: A New Treatment Option for Psoriatic Arthritis.

Rheumatol Ther. 2016 Jun;3(1):5-29. doi: 10.1007/s40744-016-0031-5. Epub 2016 Apr 23.

本文引用的文献

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验